Disposition of 26656 shares by Redmile Group, Llc of ADC Therapeutics subject to Rule 16b-3

ADCT Stock  USD 2.08  0.05  2.46%   
Slightly above 51% of ADC Therapeutics' private investors are presently thinking to get in. The analysis of overall sentiment of trading ADC Therapeutics SA stock suggests that some investors are interested at this time. ADC Therapeutics' investing sentiment can be driven by a variety of factors including economic data, ADC Therapeutics' earnings reports, geopolitical events, and overall market trends.
  
Filed transaction by ADC Therapeutics SA 10 Percent Owner. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Read at macroaxis.com
ADC insider trading alert for disposition of pre-funded warrants by Redmile Group, Llc, 10 Percent Owner, on 6th of December 2024. This event was filed by ADC Therapeutics SA with SEC on 2024-12-04. Statement of changes in beneficial ownership - SEC Form 4

Cash Flow Correlation

ADC Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the ADC Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.
Click cells to compare fundamentals

ADC Therapeutics Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards ADC Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

ADC Therapeutics Fundamental Analysis

We analyze ADC Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ADC Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ADC Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Market Capitalization

Market Capitalization Comparative Analysis

ADC Therapeutics is currently under evaluation in market capitalization category among its peers. Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.

ADC Therapeutics Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ADC Therapeutics stock to make a market-neutral strategy. Peer analysis of ADC Therapeutics could also be used in its relative valuation, which is a method of valuing ADC Therapeutics by comparing valuation metrics with similar companies.

Peers

ADC Therapeutics Related Equities

BDTXBlack Diamond   5.02   
0%
65.0%
AADIAadi Bioscience   3.33   
0%
43.0%
IPSCCentury Therapeutics   2.94   
0%
38.0%
RVMDRevolution Medicines   2.50   
0%
32.0%
DSGNDesign Therapeutics   2.20   
0%
28.0%
KURAKura Oncology   1.35   
0%
17.0%
ALVRAllovir   0.74   
0%
9.0%
AKROAkero Therapeutics   0.63   
0%
8.0%
PTGXProtagonist Therapeutics   0.51   
0%
6.0%
RAREUltragenyx   0.16   
0%
2.0%
PASGPassage Bio   0.15   
0%
1.0%
ARVNArvinas   0.11   
0%
1.0%
CRNXCrinetics Pharmaceuticals   0.57   
7.0%
0%
RNAAvidity Biosciences   1.12   
14.0%
0%
ALECAlector   1.62   
21.0%
0%
STOKStoke Therapeutics   2.50   
32.0%
0%
GBIOGeneration Bio   2.73   
35.0%
0%
ALXOAlx Oncology   7.65   
100.0%
0%

Additional Tools for ADC Stock Analysis

When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.